TITLE

Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: Results of three studies

AUTHOR(S)
Connor, Thomas H.; Sessink, Paul J. M.; Harrison, Bruce R.; Pretty, Jack R.; Peters, Byron G.; Alfaro, Raul M.; Bilos, Apple; Beckmann, Gwendolyn; Bing, Michael R.; Anderson, Lakisha M.; DeChristoforo, Robert
PUB. DATE
March 2005
SOURCE
American Journal of Health-System Pharmacy;3/1/2005, Vol. 62 Issue 5, p475
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The results of three studies that describe the external contamination of chemotherapy drug vials are presented. New techniques for the improved decontamination of vials containing cisplatin are also described. Summary. Study 1 evaluated the external contamination of drug vials with cyclophosphamide and ifosfamide in a pharmacy setting. Widespread contamination of the outside of drug vials was found with each drug. Study 2 evaluated the surface contamination of drug vials with cyclophosphamide and fluorouracil in three pharmacies. Sporadic contamination with fluorouracil was detected, while cyclophosphamide was found on most vials. In study 3, investigators compared the decontamination abilities of a standard decontamination procedure at the manufacturer level with an improved decontamination procedure and the use of sleeves to further decrease contamination. Though the methods of each study reported herein differed, the outcomes were similar. All chemotherapy drug vials studied demonstrated levels of contamination with the drug well above the limit of detection. Improved decontamination procedures, combined with the use of protective sleeves, reduced the level of platinum contamination by 90%, suggesting that standard decontamination procedures should be reconsidered. Conclusion. The results of these studies are consistent with several others that have reported contamination of the outside surface of drug vials for a number of chemotherapy drugs. Contamination can be reduced by using decontamination equipment and protective sleeves during the manufacturing process.
ACCESSION #
16223868

Tags: SURFACE contamination;  CHEMOTHERAPY;  DRUGS;  THERAPEUTICS;  PHARMACY;  PHARMACOLOGY

 

Related Articles

  • Comparative contamination study with cyclophosphamide, fluorouracil and ifosfamide: standard technique versus a proprietary closed-handling system. Tans, Birgit; Willems, Ludo // Journal of Oncology Pharmacy Practice;Dec2004, Vol. 10 Issue 4, p217 

    Introduction. In 2003 more than 55 000 preparations of injectable hazardous drugs were made in the central admixture service of the University Hospital in Leuven, Belgium. According to the literature, surface contamination occurs, despite the use of special equipment and procedures. The...

  • Adventures in drug disposition: pas seulement p�t� de foie. Sitar, Daniel S. // Canadian Journal of Physiology & Pharmacology;Dec2007, Vol. 85 Issue 12, p1215 

    Interindividual variability in drug disposition and effect has served to confound the optimization of drug therapy. Over my career, I have focused on delineating mechanisms that contribute to this variability, with the goal of improving the benefit : risk ratio when drug therapy is chosen as an...

  • CRACKING THE IBS CODE. LoBuono, Charlotte // Drug Topics;11/8/2004, Vol. 148 Issue 21, p34 

    This article explores the advances in new therapies which offer relief from the symptoms of irritable bowel syndrome (IBS), a chronic condition in which people experience recurrent episodes of abdominal pain and are associated with altered bowel movement. Pharmacists can play a significant role...

  • Drug development times not correlated with drug prices.  // PharmacoEconomics & Outcomes News;4/22/2006, Issue 501, p2 

    Provides information on a retrospective study which analyzed drug development times of 168 human therapeutic drugs. Factors thought to influence drug development time; Median total post-investigation new drug time; Market factors that influenced pricing.

  • Recent changes to FDA-approved labeling.  // American Journal of Health-System Pharmacy;4/15/2005, Vol. 62 Issue 8, p794 

    The article informs about recent changes to the Food & Drug Administration-approved labelling. It informs about bevacizumab injection. A warning was added regarding the higher frequency of cerebral infarction, transient ischemic attack, myocardial infarction, angina, and other arterial...

  • New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Hausheer, Frederick H.; Kochat, Harry; Parker, Aulma R.; Ding, Daoyuan; Yao, Shije; Hamilton, Susan E.; Petluru, Pavankumar N.; Leverett, Betsy D.; Bain, Stacey H.; Saxe, Jeffrey D. // Cancer Chemotherapy & Pharmacology. Supplement;Jul2003, Vol. 52, p3 

    Any approach applied to drug discovery and development by the medical community and pharmaceutical industry has a direct impact on the future availability of improved, novel, and curative therapies for patients with cancer. By definition, drug discovery is a complex learning process whereby...

  • Self-Care Strategies to Cope With Taste Changes After Chemotherapy. Rehwaldt, Maureen; Wickham, Rita; Purl, Sandy; Tariman, Joseph; Blendowski, Carol; Shott, Susan; Lappe, Mary // Oncology Nursing Forum;Mar2009, Vol. 36 Issue 2, pE47 

    Purpose/Objectives: To describe factors related to taste changes, to examine patients' use of a self-care suggestion sheet to manage taste changes associated with chemotherapy, and to identify potentially useful strategies for managing specific taste changes after chemotherapy.Design:...

  • New Data Presented at ASCO Show Dose-Dense Chemotherapy Including ELLENCE Extends Survival; A New Sequential Dose-Dense Chemotherapy Regimen Including ELLENCE Significantly...  // Ascribe Newswire: Medicine;6/8/2004, p105 

    New data presented at the 2004 meeting of the American Society of Clinical Oncology suggest that a chemotherapy regimen including ELLENCE may significantly improve survival in breast cancer patients at highest risk of recurrence. Results from the German AGO multi-center Phase III trial show that...

  • Clinical features and management of carboplatin-related hypersensitivity reactions in pediatric low-grade glioma. Genc, Dildar; Canpolat, Cengiz; Berrak, Su // Supportive Care in Cancer;Feb2012, Vol. 20 Issue 2, p385 

    Purpose: The effectiveness of carboplatin and vincristine chemotherapy in the treatment of low-grade glioma (LGG) is well established. However, carboplatin hypersensitivity reactions (CHR) are a major problem leading to premature cessation of therapy. We aimed to investigate the clinical...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics